TAFLUPROST
Tafluprost is an ophthalmic solution used to lower high pressure inside the eye. It helps patients with open-angle glaucoma or ocular hypertension manage their condition by reducing intraocular pressure. This medication belongs to the prostaglandin analog class and is prescribed to prevent potential eye damage caused by these elevated pressure levels.
How TAFLUPROST Works
This drug works by acting as a selective agonist for FP prostanoid receptors in the eye. When it binds to these receptors, it is believed to increase the drainage of fluid through the uveoscleral pathway. This increased outflow effectively lowers the overall pressure within the eye.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2019-08-19
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
TAFLUPROST Approval History
What TAFLUPROST Treats
2 indicationsTAFLUPROST is approved for 2 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Open-Angle Glaucoma
- Ocular Hypertension
TAFLUPROST Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in TAFLUPROST's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications TAFLUPROST treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to TAFLUPROST
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02802137 | 16/5.3.2015 | Ph 4 | completed | 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy |
| NCT01087671 | 77553 | Ph 3 | completed | Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops |
| NCT00596791 | Santen-77552 EudraCT number 2007-004872-37 | Ph 3 | completed | Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TAFLUPROST FDA Label Details
Indications & Usage
TAFLUPROST is indicated for the treatment of Open-Angle Glaucoma; Ocular Hypertension.
Looking for the branded version?
ZIOPTAN
Full clinical data, patents, trials, and competitive landscape for tafluprost.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment